Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation

A vaccine useful for the treatment or prevention of solid nonlymphoid tumor in an individual, the vaccine comprising:

• an immunotherapeutic composition for effecting B cell depletion;
• and tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response.

A composition comprising micelles comprised of tumor-associated antigen, wherein the composition is substantially free of solubilizing agents, wherein the composition is substantially free of oil, wherein the tumor-associated antigen comprises tumor cells lysed by a freeze-thaw process, and wherein the composition further comprises a pharmaceutically acceptable carrier.

The method according to 17, wherein the immunotherapeutic composition of the vaccine is administered to the individual at a time selected from the group consisting of before tumor-associated antigen of the vaccine is administered to the individual, simultaneous with the administration of tumor-associated antigen of the vaccine to the individual, subsequent to administration of tumor-associated antigen of the vaccine to the individual, and a combination thereof.

The method according to 19, wherein the vaccine further comprises an immunomodulator, and the immunomodulator is administered to the individual at a time selected from the group consisting of before tumor-associated antigen of the vaccine is administered to the individual, simultaneous with the administration of tumor-associated antigen of the vaccine to the individual, subsequent to administration of tumor-associated antigen of the vaccine to the individual, and a combination thereof.

The method according to 17, wherein the vaccine is administered parenterally.

A method for immunotherapy of an individual for treatment or prevention of solid nonlymphoid tumor, the method comprising administering to the individual a vaccine in an amount effective to reduce a TH2 response, and in an amount effective to induce a cell mediated immune response against solid nonlymphoid tumor, wherein the vaccine comprises:

• an immunotherapeutic composition for effecting B cell depletion;
• and
• tumor-associated antigen capable of inducing a cell mediated immune response comprising an immune response selected from the group consisting of a TH1 response, a cytotoxic CD8+ T cell response, and a combination thereof.

The method according to 27, wherein the immunotherapeutic composition of the vaccine is administered to the individual at a time selected from the group consisting of before tumor-associated antigen of the vaccine is administered to the individual, simultaneous with the administration of tumor-associated antigen of the vaccine to the individual, subsequent to administration of tumor-associated antigen of the vaccine to the individual, and a combination thereof.

The method according to 28, wherein the vaccine further comprises an immunomodulator, and the immunomodulator is administered to the individual at a time selected from the group consisting of before tumor-associated antigen of the vaccine is administered to the individual, simultaneous with the administration of tumor-associated antigen of the vaccine to the individual, subsequent to administration of tumor-associated antigen of the vaccine to the individual, and a combination thereof.

The method according to 27, wherein the vaccine is administered parenterally.

A method for immunotherapy of an individual for treatment or prevention of solid nonlymphoid tumor, the method comprising administering to the individual a vaccine comprising:

• a priming dose comprised of a composition selected from the group consisting of an immunotherapeutic composition, anti-CD4 monoclonal antibody, and a combination thereof;
• and
• an immunizing dose comprised of tumor-associated antigen capable of inducing a cell mediated immune response comprising an immune response selected from the group consisting of a TH1 response, a cytotoxic CD8+ T cell response, and a combination thereof.

A method for priming the immune system of an individual, the method comprises:

• administering to the individual a priming dose, wherein the priming dose comprises a composition selected from the group consisting of an immunotherapeutic composition, anti-CD4 monoclonal antibody, and a combination thereof;
• wherein the priming dose is administered in an amount effective to modulate the individual's immune system to respond with induction of a cell mediated immune response upon administration of an immunizing dose of tumor-associated antigen to the individual.

A vaccination kit comprising in separate containers:

• (a) a priming dose comprising a composition selected from the group consisting of an immunotherapeutic composition, anti-CD4 monoclonal antibody, and a combination thereof;
• and
• (b) an immunizing dose comprising tumor-associated antigen.